Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1965 1
1966 1
1967 1
1971 1
1973 1
1974 1
1975 1
1977 3
1978 10
1979 5
1980 4
1981 6
1982 9
1983 14
1984 2
1985 12
1986 3
1987 2
1988 4
1989 5
1990 6
1991 7
1992 2
1993 7
1994 12
1995 4
1996 7
1997 3
1998 4
1999 7
2000 3
2001 8
2002 14
2003 8
2004 12
2005 8
2006 9
2007 11
2008 12
2009 11
2010 13
2011 22
2012 18
2013 24
2014 19
2015 26
2016 23
2017 15
2018 19
2019 20
2020 18
2021 23
2022 26
2023 32
2024 26
2025 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

547 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Eskander RN, et al. Among authors: john vs. N Engl J Med. 2023 Jun 8;388(23):2159-2170. doi: 10.1056/NEJMoa2302312. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972022 Free PMC article. Clinical Trial.
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, Lokich E, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Baghdadi TA, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Eskander RN, et al. Among authors: john vs. Nat Med. 2025 May;31(5):1539-1546. doi: 10.1038/s41591-025-03566-1. Epub 2025 Mar 5. Nat Med. 2025. PMID: 40044930 Clinical Trial.
Correspondence.
Todorich B, Thanos A, Yonekawa Y, Thomas BJ, Faia LJ, Chang E, Shulman J, Olsen KR, Blair MP, Shapiro MP, Ferrone P, Vajzovic L, Toth CA, Lee TC, Robinson J, Hubbard B, Kondo H, Besirli CG, Nudleman E, Wong SC, Kusaka S, Walsh M, Chan RVP, Berrocal A, Caputo G, Murray TG, Sears J, Schunemann R, Harper CA 3rd, Kychental A, Dorta P, Cernichiaro-Espinosa LA, Wu WC, Campbell JP, Martinez-Castellanos MA, Quiroz-Mercado H, Hayashi H, Quiram P, Amphornphruet A, Hartnett ME, Tsui I, Ells A, John V, Moshfeghi D, Capone A Jr, Drenser KA, Trese MT. Todorich B, et al. Among authors: john v. Retina. 2017 May;37(5):e52-e54. doi: 10.1097/IAE.0000000000001602. Retina. 2017. PMID: 28358752 Free PMC article. No abstract available.
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, Butowski NA, Sumrall A, Shonka N, Harrison RA, de Groot J, Mehta M, Hall MD, Daghistani D, Cloughesy TF, Ellingson BM, Beccaria K, Varlet P, Kim MM, Umemura Y, Garton H, Franson A, Schwartz J, Jain R, Kachman M, Baum H, Burant CF, Mottl SL, Cartaxo RT, John V, Messinger D, Qin T, Peterson E, Sajjakulnukit P, Ravi K, Waugh A, Walling D, Ding Y, Xia Z, Schwendeman A, Hawes D, Yang F, Judkins AR, Wahl D, Lyssiotis CA, de la Nava D, Alonso MM, Eze A, Spitzer J, Schmidt SV, Duchatel RJ, Dun MD, Cain JE, Jiang L, Stopka SA, Baquer G, Regan MS, Filbin MG, Agar NYR, Zhao L, Kumar-Sinha C, Mody R, Chinnaiyan A, Kurokawa R, Pratt D, Yadav VN, Grill J, Kline C, Mueller S, Resnick A, Nazarian J, Allen JE, Odia Y, Gardner SL, Koschmann C. Venneti S, et al. Among authors: john v. Cancer Discov. 2023 Nov 1;13(11):2370-2393. doi: 10.1158/2159-8290.CD-23-0131. Cancer Discov. 2023. PMID: 37584601 Free PMC article.
Guest Editorial.
John V. John V. J Indiana Dent Assoc. 2016 Winter;95(1):7. J Indiana Dent Assoc. 2016. PMID: 26939406 No abstract available.
Immunity to salmonellosis.
Dougan G, John V, Palmer S, Mastroeni P. Dougan G, et al. Among authors: john v. Immunol Rev. 2011 Mar;240(1):196-210. doi: 10.1111/j.1600-065X.2010.00999.x. Immunol Rev. 2011. PMID: 21349095 Review.
Periodontal Health and Systemic Conditions.
Lim G, Janu U, Chiou LL, Gandhi KK, Palomo L, John V. Lim G, et al. Among authors: john v. Dent J (Basel). 2020 Nov 19;8(4):130. doi: 10.3390/dj8040130. Dent J (Basel). 2020. PMID: 33227918 Free PMC article. Review.
Liquid biopsy in pediatric brain tumors.
Tripathy A, John V, Wadden J, Kong S, Sharba S, Koschmann C. Tripathy A, et al. Among authors: john v. Front Genet. 2023 Jan 6;13:1114762. doi: 10.3389/fgene.2022.1114762. eCollection 2022. Front Genet. 2023. PMID: 36685825 Free PMC article. Review.
Eyeball simulator for extraocular muscles.
Khadia A, Thangaraju D, Gupta I, Mouttappa F, Veena K, Rengaraj V, Kumaresan Y, Poorani R, John VS. Khadia A, et al. Among authors: john vs. Indian J Ophthalmol. 2023 Feb;71(2):653-656. doi: 10.4103/ijo.IJO_1810_22. Indian J Ophthalmol. 2023. PMID: 36727381 Free PMC article.
547 results